Evolutionarily Repurposed Networks Reveal the Well-Known Antifungal Drug Thiabendazole to Be a Novel Vascular Disrupting Agent

PLoS Biology

Volumn 10, Issue 8, 2012, Pages

  Cha, Hye Ji ^a   Byrom, Michelle ^a   Mead, Paul E ^b   Ellington, Andrew D ^a   Wallingford, John B ^a   Marcotte, Edward M ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIABENDAZOLE; VASCULAR TARGETING AGENT;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DISEASE MODEL; DRUG RESEARCH; EMBRYO; EVOLUTIONARY REPURPOSED GENE NETWORK; FEMALE; FIBROSARCOMA; GENETIC CONSERVATION; GENETIC PARAMETERS; HUMAN; HUMAN CELL; MYCOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; TIME LAPSE IMAGING; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; FIBROSARCOMA; GENE KNOCKDOWN TECHNIQUES; GENE REGULATORY NETWORKS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LOVASTATIN; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; RAB GTP-BINDING PROTEINS; THIABENDAZOLE; TIME-LAPSE IMAGING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS; XENOPUS LAEVIS;

ANIMALIA; VERTEBRATA;

EID: 84865740441     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001379     Document Type: Article

References (49)

1. McGary KL, Park TJ, Woods JO, Cha HJ, Wallingford JB, et al. (2010) Systematic discovery of nonobvious human disease models through orthologous phenotypes. Proc Natl Acad Sci U S A 107: 6544-6549.
2. Carmeliet P, Jain RK, (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473: 298-307.
3. Kerbel RS, (2008) Tumor angiogenesis. N Engl J Med 358: 2039-2049.
4. Heath VL, Bicknell R, (2009) Anticancer strategies involving the vasculature. Nat Rev Clin Oncol 6: 395-404.
5. Folkman J, (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286.
6. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, et al. (2008) Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 113: 1953-1968.
7. Chi AS, Sorensen AG, Jain RK, Batchelor TT, (2009) Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 14: 621-636.
8. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, et al. (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622.
9. Depasquale I, Wheatley DN, (2006) Action of Lovastatin (Mevinolin) on an in vitro model of angiogenesis and its co-culture with malignant melanoma cell lines. Cancer Cell Int 6: 9.
10. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, et al. (2002) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 91: 143-150.
11. Shellman YG, Ribble D, Miller L, Gendall J, Vanbuskirk K, et al. (2005) Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res 15: 83-89.
12. Splichal JE, Ornstein DL, Gia Hong-Dice Y, Downs JR, Fischer JR, (2001) Lovastatin for the prevention of melanoma: Analysis of AFCAPS/TexCAPS. Am Soc Clin Oncol Abstract pp. 1397.
13. Hillenmeyer ME, Fung E, Wildenhain J, Pierce SE, Hoon S, et al. (2008) The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science 320: 362-365.
14. Edwards IR, Ferry DG, Temple WA (1991) Fungicides and Related Compounds. In: Hayes WJ, Laws ER, editors. Handbook of Pesticide Toxicology. New York: Academic Press, Inc.
15. Gosselin RE, Smith RP, Hodge HC (1984) Clinical Toxicology of Commercial Products. Baltimore, MD: Williams and Wilkins.
16. Cleaver O, Tonissen KF, Saha MS, Krieg PA, (1997) Neovascularization of the Xenopus embryo. Dev Dyn 210: 66-77.
17. Ny A, Autiero M, Carmeliet P, (2006) Zebrafish and Xenopus tadpoles: small animal models to study angiogenesis and lymphangiogenesis. Exp Cell Res 312: 684-693.
18. Kalin RE, Banziger-Tobler NE, Detmar M, Brandli AW, (2009) An in vivo chemical library screen in Xenopus tadpoles reveals novel pathways involved in angiogenesis and lymphangiogenesis. Blood 114: 1110-1122.
19. Doherty JR, Johnson Hamlet MR, Kuliyev E, Mead PE, (2007) A flk-1 promoter/enhancer reporter transgenic Xenopus laevis generated using the Sleeping Beauty transposon system: an in vivo model for vascular studies. Dev Dyn 236: 2808-2817.
20. Levine AJ, Munoz-Sanjuan I, Bell E, North AJ, Brivanlou AH, (2003) Fluorescent labeling of endothelial cells allows in vivo, continuous characterization of the vascular development of Xenopus laevis. Dev Biol 254: 50-67.
21. Tozer GM, Kanthou C, Baguley BC, (2005) Disrupting tumour blood vessels. Nat Rev Cancer 5: 423-435.
22. Hinnen P, Eskens FA, (2007) Vascular disrupting agents in clinical development. Br J Cancer 96: 1159-1165.
23. Kieserman EK, Lee C, Gray RS, Park TJ, Wallingford JB, (2010) High-magnification in vivo imaging of Xenopus embryos for cell and developmental biology. Cold Spring Harb Protoc 2010: pdb prot5427.
24. Ching LM, Cao Z, Kieda C, Zwain S, Jameson MB, et al. (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br J Cancer 86: 1937-1942.
25. Kanthou C, Tozer GM, (2002) The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99: 2060-2069.
26. Jaffe AB, Hall A, (2005) Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 21: 247-269.
27. Zhou Q, Zhai Y, Lou J, Liu M, Pang X, et al. (2011) Thiabendazole inhibits ubiquinone reduction activity of mitochondrial respiratory complex II via a water molecule mediated binding feature. Protein Cell 2: 531-542.
28. Davidse LC, (1986) Benzimidazole fungicides: Mechanism of action and biological impact. Ann Rev Phytopathol 24: 43-65.
29. Davidse LC, Flach W, (1978) Interaction of thiabendazole with fungal tubulin. Biochim Biophys Acta 543: 82-90.
30. Pisano C, Battistoni A, Antoccia A, Degrassi F, Tanzarella C, (2000) Changes in microtubule organization after exposure to a benzimidazole derivative in Chinese hamster cells. Mutagenesis 15: 507-515.
31. Sawin KE, Nurse P, (1998) Regulation of cell polarity by microtubules in fission yeast. J Cell Biol 142: 457-471.
32. Schwartz EL, (2009) Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15: 2594-2601.
33. Ren X, Dai M, Lin LP, Li PK, Ding J, (2009) Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent. Br J Pharmacol 156: 1228-1238.
34. Bayless KJ, Davis GE, (2003) Sphingosine-1-phosphate markedly induces matrix metalloproteinase and integrin-dependent human endothelial cell invasion and lumen formation in three-dimensional collagen and fibrin matrices. Biochem Biophys Res Commun 312: 903-913.
35. Birukova AA, Adyshev D, Gorshkov B, Bokoch GM, Birukov KG, et al. (2006) GEF-H1 is involved in agonist-induced human pulmonary endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 290: L540-548.
36. Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, et al. (2011) Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29: 2965-2971.
37. Crawford Y, Ferrara N, (2009) VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 335: 261-269.
38. Couffinhal T, Dufourcq P, Barandon L, Leroux L, Duplaa C, (2009) Mouse models to study angiogenesis in the context of cardiovascular diseases. Front Biosci 14: 3310-3325.
39. Wall A, Persigehl T, Hauff P, Licha K, Schirner M, et al. (2008) Differentiation of angiogenic burden in human cancer xenografts using a perfusion-type optical contrast agent (SIDAG). Breast Cancer Res 10: R23.
40. Griggs J, Skepper JN, Smith GA, Brindle KM, Metcalfe JC, et al. (2002) Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am J Pathol 160: 1097-1103.
41. Randall JC, Young SL (2006) Vascular-Targeted Therapies in Oncology: John Wiley & Sons, Ltd.
42. Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ Jr, et al. (2007) Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2: 263-270.
43. Kumar MS, Kumar PM, Sarnaik HM, Sadhukhan AK, (2000) A rapid technique for screening of lovastatin-producing strains of Aspergillus terreus by agar plug and Neurospora crassa bioassay. J Microbiol Methods 40: 99-104.
44. Sive HL, Grainger RM, Harland RM (2000) Early Development of Xenopus laevis: A laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Press.
45. Bruhl T, Urbich C, Aicher D, Acker-Palmer A, Zeiher AM, et al. (2004) Homeobox A9 transcriptionally regulates the EphB4 receptor to modulate endothelial cell migration and tube formation. Circ Res 94: 743-751.
46. Lee C, Kieserman E, Gray RS, Park TJ, Wallingford J, (2008) Whole-mount fluorescence immunocytochemistry on Xenopus embryos. CSH Protoc 2008: pdb prot4957.
47. Flicek P, Aken BL, Ballester B, Beal K, Bragin E, et al. (2010) Ensembl's 10th year. Nucleic Acids Res 38: D557-562.
48. Kall L, Canterbury JD, Weston J, Noble WS, MacCoss MJ, (2007) Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat Methods 4: 923-925.
49. Lu P, Vogel C, Wang R, Yao X, Marcotte EM, (2007) Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation. Nat Biotechnol 25: 117-124.